病毒学抑制的HIV感染者从利托那韦增效PI转换为多替拉韦的随机对照研究
这项随机多中心研究纳入73例骨量减少或骨质疏松且病毒学抑制的HIV感染者,随机转换为多替拉韦(DOLU组,n=37)或继续使用利托那韦增效PI(PI组,n=36)。48周时两组病毒抑制率分别为97.3%和91.7%,股骨和腰椎骨密度变化无显著差异,但DOLU组甘油三酯更低、HDL胆固醇更高。
要点
- 病毒学抑制的HIV感染者从利托那韦增效PI转换为多替拉韦,48周病毒抑制率维持良好。
- 转换后股骨和腰椎骨密度变化与继续PI方案相比无显著差异。
- 转换后甘油三酯显著降低、HDL胆固醇升高,血脂谱改善。
核心结论
- 在多替拉韦联合Kivexa®方案在病毒学抑制且接受PI方案的患者中安全且耐受良好。
- 血脂谱更好,但骨密度无显著变化,可能因随访时间较短。
研究设计与样本
- 随机、多中心研究,纳入73例病毒学抑制且骨量减少/骨质疏松的HIV感染者。
- 随机分为转换为多替拉韦组(DOLU组,n=37)或继续利托那韦增效PI组(PI组,n=36)。
- 主要评估骨密度变化,次要评估抗病毒疗效和安全性,随访48周。
主要发现
- 48周时,DOLU组和PI组分别有97.3%和91.7%维持病毒抑制(快照分析,ITT,M=F)。
- 股骨和腰椎骨密度从基线至48周的百分比变化组间无显著差异(P=0.56和P=0.29)。
- DOLU组腰椎骨密度改善1.43%(-1.36; 2.92),PI组为0.12%(-2.83; 2.89)。
- 骨转换标志物值无显著变化。
- 48周时DOLU组甘油三酯较低(P<0.001),HDL胆固醇较高(P=0.027)。
关键数值与推荐
- 48周病毒抑制率:DOLU组97.3% vs PI组91.7%(快照分析,ITT,M=F)。
- 股骨骨密度变化组间比较P=0.56,腰椎骨密度变化组间比较P=0.29。
- 甘油三酯组间比较P<0.001,HDL胆固醇组间比较P=0.027。
临床怎么用
- 对于病毒学抑制且接受利托那韦增效PI方案的HIV感染者,转换为多替拉韦联合Kivexa®是安全可行的选择。
- 转换后可能改善血脂谱(甘油三酯降低、HDL升高),但短期内骨密度无显著获益。
局限性
- 随访时间较短(48周),可能不足以观察到骨密度的显著变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed. OBJECTIVES: The principal aim was to assess the evolution of bone mineral density (BMD) when switching from a ritonavir-boosted PI to dolutegravir in HIV-infected patients with osteopenia or osteoporosis. The secondary objective was to assess the antiviral efficacy and safety of the switch therapy. METHODS: This randomized, multicentre study assessed changes in BMD, bone turnover markers, and antiviral efficacy and safety in 73 virologically suppressed patients with osteopenia/osteoporosis taking a ritonavir-boosted PI plus abacavir/lamivudine who were randomized to switch from PI to dolutegravir (DOLU group, n = 37) or continue with a PI (PI group, n = 36). Clinical Trials: NCT02577042. RESULTS: One and three patients from the DOLU and PI groups, respectively, withdrew prematurely (unrelated to treatment). At 48 weeks, 97.3% versus 91.7%, respectively, maintained viral suppression (snapshot analysis, ITT, M = F). No significant differences were seen between the groups in percentage change from baseline to week 48 in femoral ( P = 0.56) and lumbar spine ( P = 0.29) BMD, although lumbar spine BMD improved by 1.43% (-1.36; 2.92) in the DOLU group [0.12% (-2.83; 2.89) in the PI group]. Bone marker values did not vary significantly. At week 48, triglycerides were lower ( P < 0.001) and HDL cholesterol higher ( P = 0.027) in the DOLU group. CONCLUSIONS: Dolutegravir + Kivexa ® was safe and well-tolerated in virologically suppressed patients receiving a PI-based regimen. The lipid profile was better, albeit without significant changes in BMD, probably because of the short follow-up.
引用
- Negredo E, Estrada V, Domingo P, et al. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. J Antimicrob Chemother. 2017. PMID: 27999056. doi:10.1093/jac/dkw504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。